The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Andrew Redington, The Hospital for Sick Children
ClinicalTrials.gov Identifier:
NCT01164618
First received: July 14, 2010
Last updated: August 14, 2013
Last verified: August 2013
  Purpose

The purpose of this study is to assess the effects of repeated RIPC and exercise, on exercise performance, skeletal muscle responses and circulating cellular and humoral biology in humans


Condition Intervention Phase
Ischemic Preconditioning
Procedure: Remote ischemic preconditioning (RIPC)
Other: Exercise
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response

Resource links provided by NLM:


Further study details as provided by The Hospital for Sick Children:

Primary Outcome Measures:
  • Ischemia-reperfusion injury tolerance [ Time Frame: Day 1 of the Excercise intervention ] [ Designated as safety issue: No ]

    This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.

    This measure will be compared over time within groups and between groups.


  • Ischemia-reperfusion injury tolerance [ Time Frame: Day 1 of the RIPC intervention ] [ Designated as safety issue: No ]

    This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.

    This measure will be compared over time within groups and between groups.


  • Ischemia-reperfusion injury tolerance [ Time Frame: Day 2 of the Excercise intervention ] [ Designated as safety issue: No ]

    This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.

    This measure will be compared over time within groups and between groups.


  • Ischemia-reperfusion injury tolerance [ Time Frame: Day 2 of the RIPC intervention ] [ Designated as safety issue: No ]

    This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.

    This measure will be compared over time within groups and between groups.


  • Ischemia-reperfusion injury tolerance [ Time Frame: Day 10 of the Excercise intervention ] [ Designated as safety issue: No ]

    This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.

    This measure will be compared over time within groups and between groups.


  • Ischemia-reperfusion injury tolerance [ Time Frame: Day 10 of the RIPC intervention ] [ Designated as safety issue: No ]

    This will be done to assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.

    This measure will be compared over time within groups and between groups.



Secondary Outcome Measures:
  • Change in skeletal muscle metabolic parameters metabolism as measured by 31P-MRS and BOLD fMRI over time within groups and between groups [ Time Frame: Days 1, 2 and 10 days of each intervention (RIPC and Excercise) ] [ Designated as safety issue: No ]
  • Neutrophil Function - adhesion, phagocytotic index, and superoxide production over time within groups and between groups [ Time Frame: Days 1, 2 and 10 of each intervention (RIPC and Excercise) ] [ Designated as safety issue: No ]
  • Neutrophil Gene Expression over time within groups and between groups [ Time Frame: Days 1, 2 and 10 of each intervention (RIPC and Excercise) ] [ Designated as safety issue: No ]
  • Ischemia-reperfusion injury tolerance [ Time Frame: Days 1, 2 and 10 of each intervention (RIPC and Excercise) ] [ Designated as safety issue: No ]
    We will assess whether chronic preconditioning in humans generates a circulating effector(s) responsible for the generation of cardioprotection in our mouse model of ischemia-reperfusion injury.

  • Exercise Capacity (VO2max) over time within groups and between groups [ Time Frame: Day 10 of each intervention (RIPC and Exercise) ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: May 2010
Estimated Study Completion Date: January 2014
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
Procedure: Remote ischemic preconditioning (RIPC)
RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
Other: Exercise
Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
Experimental: Group 2
The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
Procedure: Remote ischemic preconditioning (RIPC)
RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
Other: Exercise
Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.

Detailed Description:

Remote ischemic preconditioning (RIPC) results in a powerful and widespread protective effect against subsequent prolonged ischemia-reperfusion (IR) injury of distant organs and systemic inflammatory responses, both of which are key elements in the evolution of local and multiorgan effects of many clinical IR syndromes. The signal transduction within the target organ to generate ischemia tolerance, and the effects of RIPC on systemic anti-inflammatory pathways, however, remain to be elucidated fully. Particularly, data regarding the mechanisms of 'second window' protection (a resurgence of protection 24-72 hrs after the initial RIPC stimulus) is scant; even less is known of the effects of repeated RIPC, and a potential 'third window' of protection. Our preliminary data and several recent publications have shown that the biology of RIPC and exercise show considerable overlap. This research has raised the possibility of a reciprocal effect between RIPC and exercise, with chronic exercise being a model of the potential effects of 'chronic preconditioning'. This is relevant, as repeated RIPC might be a strategy to improve exercise function in those with limited exercise tolerance e.g. heart failure.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years,
  2. Informed consent

Exclusion Criteria:

  1. Contraindication to exercise,
  2. Vigorous aerobic/anaerobic exercise in duration of ≥15 minutes during the 21 days prior to commencement of the study, or either of the RIPC or exercise protocol arms,
  3. Overt viral or bacterial infection in the 10 days prior to commencement of the study, or during either of the RIPC or exercise protocol arms,
  4. Alcohol and/or caffeine consumption in the 10 days prior to, or at any time during the study period
  5. Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01164618

Locations
Canada, Ontario
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
Sponsors and Collaborators
The Hospital for Sick Children
Investigators
Principal Investigator: Andrew Redington, MD The Hospital for Sick Children, Toronto Canada
  More Information

No publications provided

Responsible Party: Andrew Redington, Head, Heart Centre-Cardiology Division, The Hospital for Sick Children
ClinicalTrials.gov Identifier: NCT01164618     History of Changes
Other Study ID Numbers: 1000015862
Study First Received: July 14, 2010
Last Updated: August 14, 2013
Health Authority: Canada: Ethics Review Committee

Keywords provided by The Hospital for Sick Children:
pediatrics
Remote ischemic preconditioning

ClinicalTrials.gov processed this record on October 16, 2014